Travel Vaccines

Global Travel Vaccines Market to Reach US$18.8 Billion by 2030

The global market for Travel Vaccines estimated at US$13.2 Billion in the year 2024, is expected to reach US$18.8 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Influenza Vaccines, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$9.4 Billion by the end of the analysis period. Growth in the Diphtheria Vaccines segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 9.4% CAGR

The Travel Vaccines market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Travel Vaccines Market - Key Trends & Drivers Summarized

Why Are Travel Vaccines Becoming a Prerequisite for International Mobility?

Travel vaccines have emerged as vital safeguards in a globalized world, where the ease of international movement also raises the risk of infectious disease transmission. Vaccines for yellow fever, hepatitis A and B, typhoid, rabies, cholera, and Japanese encephalitis are not only recommended but often mandatory for travelers visiting specific countries. These immunizations protect travelers and host populations alike, acting as essential public health tools in global disease containment.

Heightened awareness following the COVID-19 pandemic has significantly increased the uptake of pre-travel medical consultations and vaccination plans. As governments tighten cross-border health checks, travelers are more willing to comply with immunization schedules. Multilateral health bodies and travel medicine clinics are reinforcing guidelines, and digital vaccine certification systems have been deployed to validate traveler readiness, particularly in higher-risk regions of Africa, Asia, and Latin America.

How Are Technological and Formulation Advances Enhancing Vaccine Uptake?

The field of vaccinology is undergoing significant innovation, with mRNA platforms, thermostable formulations, and combination vaccines being tailored for travel use. These advances are reducing cold chain dependency, extending shelf life, and simplifying dosage schedules—key benefits for last-minute or remote-area travelers. Some travel vaccines now require just one dose or offer oral options, improving compliance and accessibility.

Another key development is the integration of electronic health records and mobile apps that automate reminders and provide guidance based on destination-specific risks. Clinics are offering bundled packages with tailored vaccine plans and digital certificates. Additionally, prefilled syringes, microneedle patches, and intranasal formulations are enhancing administration safety and efficiency, particularly for pediatric and elderly populations.

Which Traveler Segments and Destinations Are Fueling Demand?

Tourists, humanitarian workers, international students, and business travelers to high-risk regions are primary consumers of travel vaccines. The surge in eco-tourism, rural tourism, and adventure travel increases exposure to vector-borne diseases and zoonoses, driving vaccination needs. Additionally, corporate travel to emerging markets and global supply chain expansion has led to a rise in enterprise-funded immunization programs.

The demand is also rising in non-traditional traveler categories such as digital nomads, missionaries, and expatriates, who require long-term or multiple booster doses. Destination-specific health risks and outbreak alerts frequently alter vaccine requirements, prompting last-minute surges in demand at travel clinics. Furthermore, national mandates and health advisories continue to influence both vaccine availability and traveler compliance.

The Growth in the Travel Vaccines Market Is Driven by Several Factors…

Expansion in global travel volumes, heightened awareness of region-specific disease risks, and stricter cross-border health protocols are key growth enablers. Advancements in vaccine platforms—including mRNA, conjugate, and recombinant technologies—are increasing the availability and efficacy of travel vaccines. The rise in adventure, eco-tourism, and off-grid travel is pushing more travelers into regions with higher pathogen exposure, necessitating preemptive immunization. Digital health tools and mobile vaccine passport systems are streamlining pre-travel compliance, encouraging more consistent uptake. Additionally, institutional support from governments and global health organizations, alongside private sector initiatives in workforce protection, are further accelerating market momentum.

SCOPE OF STUDY:

The report analyzes the Travel Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Type (Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines, Typhoid & Other Vaccines); End-Use (Adult End-Use, Pediatric End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• ALK-Abelló A/S
• AstraZeneca PLC
• Bavarian Nordic A/S
• CSL Limited
• F.?Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Janssen Pharmaceuticals (J&J)
• Merck & Co., Inc.
• Moderna Inc. (if included)
• Novartis AG
• Novavax, Inc.
• Pfizer Inc.
• Qiagen NV
• Sanofi S.A.
• Valneva SE

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.